Literature DB >> 7468157

Lisuride in the treatment of Parkinsonism.

M Schachter, M P Sheehy, J D Parkes, C D Marsden.   

Abstract

Lisuride 1.2-4.8 mg daily was given to 10 patients with severe Parkinsonism for up to 9 months. All had been taking bromocriptine and eight had been taking levodopa combined with carbidopa. Total replacement of bromocriptine by lisuride was achieved in every case, but partial or total levodopa replacement was possible only in five patients. Lisuride 1 mg has approximately the same antiparkinsonian activity as bromocriptine 15 mg or levodopa 250-500 mg combined with carbidopa, but the duration of action of each dose is short, and gastro-intestinal and neuropsychiatric side effects are common. However, lisuride i.v. may be of considerable value in the emergency treatment of severe Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7468157     DOI: 10.1111/j.1600-0404.1980.tb03050.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  1 in total

1.  Domperidone.

Authors:  P Critchley; N Langdon; J D Parkes; N P Quinn; J S Shindler; C D Marsden
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.